GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » EBIT

InNexus Biotechnology (InNexus Biotechnology) EBIT : $-2.22 Mil (TTM As of Mar. 2011)


View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology EBIT?

InNexus Biotechnology's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2011 was $-0.32 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2011 was $-2.22 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. InNexus Biotechnology's annualized ROC % for the quarter that ended in Mar. 2011 was -13.15%. InNexus Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2011 was -206.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.


InNexus Biotechnology EBIT Historical Data

The historical data trend for InNexus Biotechnology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology EBIT Chart

InNexus Biotechnology Annual Data
Trend Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09 Jun10
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.40 -5.42 -5.62 -5.95 -3.79

InNexus Biotechnology Quarterly Data
Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.03 -1.15 -0.34 -0.41 -0.32

Competitive Comparison of InNexus Biotechnology's EBIT

For the Biotechnology subindustry, InNexus Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InNexus Biotechnology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InNexus Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where InNexus Biotechnology's EV-to-EBIT falls into.



InNexus Biotechnology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InNexus Biotechnology  (GREY:IXSBF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

InNexus Biotechnology's annualized ROC % for the quarter that ended in Mar. 2011 is calculated as:

ROC % (Q: Mar. 2011 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2010 ) + Invested Capital (Q: Mar. 2011 ))/ count )
=-1.264 * ( 1 - % )/( (9.414 + 9.809)/ 2 )
=-1.264/9.6115
=-13.15 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2011) data.

2. Joel Greenblatt's definition of Return on Capital:

InNexus Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2011 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2011 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2010  Q: Mar. 2011
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.264/( ( (0.66 + max(-2.665, 0)) + (0.565 + max(-2.929, 0)) )/ 2 )
=-1.264/( ( 0.66 + 0.565 )/ 2 )
=-1.264/0.6125
=-206.37 %

where Working Capital is:

Working Capital(Q: Dec. 2010 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (2.665 + 0 + 0)
=-2.665

Working Capital(Q: Mar. 2011 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.003) - (2.934 + 0 + -0.0019999999999989)
=-2.929

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2011) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

InNexus Biotechnology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2011 )
=-2.221/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InNexus Biotechnology EBIT Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


InNexus Biotechnology (InNexus Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7
InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology (InNexus Biotechnology) Headlines

No Headlines